Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Exclusion Criteria

• •Patient has a diagnosis of recurrent brain metastases.
• •The patient has an absolute neutrophil count less than or equal to 1.5 X 10 9/L.
• •The patient has a screening platelet count less than 100,000/uL.
• •The patient has a screening bilirubin greater than 1.6 mg/dL.
• •The patient has a screening creatinine greater than 2.25 mg/dL in men and 1.8 mg/dL in women.
• •The patient has a screening ALT/AST greater than 2.5 times the upper limit of the laboratory reference range.
• •The patient has an unstable medical condition or significant comorbid pathophysiology (e.g. active infection, poorly controlled diabetes, unstable angina, severe heart failure) that would interfere with his/her participation in the study.
• •The patient is enrolled, or plans to enroll, in a concurrent treatment protocol with another investigational product.
• •The patient has received prior chemotherapy or radiation therapy within two weeks of beginning WBRT on protocol.
• •The patient is allergic to gadolinium contrast.
• •More than 21 days has or will elapse between the brain MRI documenting the brain metastases and the initiation of WBRT.